Open Access

EDITORIAL

Kevin R. Loughlin
Canadian Journal of Urology, Vol.26, No.3, pp. 9746-9747, 2019
Abstract This article has no abstract. More >

View

26

Download

27

Open Access

LEGENDS IN UROLOGY

Mani Menon
Canadian Journal of Urology, Vol.26, No.3, pp. 9748-9751, 2019
Abstract This article has no abstract. More >

View

23

Download

23

Open Access

ARTICLE

Kassem S. Faraj¹, Haidar M. Abdul-Muhsin¹, Anojan K. Navaratnam¹, Kyle M. Rose¹, Jeffrey Stagg², Thai H. Ho³, Alan H. Bryce³, Scott M. Cheney¹, Mark D. Tyson¹, Erik P. Castle¹
Canadian Journal of Urology, Vol.26, No.3, pp. 9752-9757, 2019
Abstract Introduction: The management of malignant mesothelioma of the tunica vaginalis (MMTVT) is not clearly defined. Retroperitoneal lymph node dissection has been reported as a potential management option. Herein we present our experience with robot-assisted retroperitoneal lymph node dissection (RARPLND) in our series of patients with MMTVT.
Materials and methods: The Mayo Clinic cancer registry was queried from 1972-present for all patients who had a diagnosis of MMTVT. Six patients were identified, five of whom were treated with RPLND, where four underwent RARPLND.
Results: In five patients who underwent RPLND, the median age was 50 years (IQR 34-51). Four… More >

View

25

Download

25

Open Access

ARTICLE

Syed Alam¹, Joseph Tortora², Ilene Staff², Tara McLaughlin¹, Joseph Wagner¹
Canadian Journal of Urology, Vol.26, No.3, pp. 9758-9762, 2019
Abstract Introduction: OncotypeDx, Prolaris, and Decipher have each been validated to predict outcomes and guide treatment for patients with clinically localized prostate cancer, but they have yet to be compared to one another. Here we assess the correspondence between the results of each.
Materials and methods: We performed a retrospective chart review to identify patients who underwent at least two of the three genomic tests at Hartford Hospital between 2014 and 2017. We used test-specific definitions of a favorable prediction for each to compare the percent agreement between each pair. Results were also compared to treatment recommendations based… More >

View

26

Download

28

Open Access

ARTICLE

Nachiketh Soodana-Prakash¹, R. Patricia Castillo², Isildinha M. Reis^3,4, Radka Stoyanova^3,5, Deukwoo Kwon³, Maria C. Velasquez², Bruno Nahar¹, Pratik Kannabur¹, Taylor A. Johnson¹, Sanjaya K. Swain^1,3, Natalie Ben-Yakar¹, Vivek Venkatramani¹, Chad Ritch^1,3, Ramgopal Satyanarayana^1,3, Mark L. Gonzalgo^1,3, Dipen J. Parekh^1,3, Leonardo Bittencourt⁶, Sanoj Punnen^1,3
Canadian Journal of Urology, Vol.26, No.3, pp. 9763-9768, 2019
Abstract Introduction: To assess the secondary sequence rule in The Prostate Imaging Reporting Data System (PI-RADS) version 2 by comparing the detection of Grade group 1+ (GG1+) and 2+ (GG2+) cancers in PI-RADS 3, an upgraded PI-RADS 4, and true (non-upgraded) PI-RADS 4 targets.
Materials and methods: We analyzed a total of 589 lesions scored as PI-RADS 3 or 4 obtained from 434 men who underwent mpMRI-US fusion biopsy from September 2015 to November 2017 for evaluation of GG1+ and GG2+ prostate cancer. PI-RADS 4 lesions were differentiated into those that were “upgraded” to PI-RADS 4 based on… More >

View

25

Download

24

Open Access

ARTICLE

Matthew R. Epstein, Thomas F. Monaghan, Johnathan A. Khusid, Nicholas R. Suss, Christina W. Agudelo, Kyle P. Michelson, Zhan D. Wu, Fred Gong, Jeffrey P. Weiss
Canadian Journal of Urology, Vol.26, No.3, pp. 9769-9773, 2019
Abstract Introduction: Much of what is known about the etiology of nocturia (i.e., nocturnal polyuria [NP], small bladder capacity [SBC], etc.) at the population level stems from the Krimpen study, which enrolled aging males from a homogenous municipality in the Netherlands. Given the higher prevalence of benign prostatic hyperplasia and overactive bladder in black versus white males in population research, we aim to test the hypothesis that black males seeking treatment for lower urinary tract symptoms (LUTS) are more likely to have nocturia owing to SBC.
Materials and methods: We retrospectively analyzed 24-hour frequency-volume charts (FVCs) completed by… More >

View

25

Download

24

Open Access

ARTICLE

Senad Kalkan¹, William I. Jaffe², Vannita Simma-Chiang³, Eric S. W. Li⁴, Jerry G. Blaivas³
Canadian Journal of Urology, Vol.26, No.3, pp. 9774-9780, 2019
Abstract Introduction: There is a paucity of data about augmentation cystoplasty (AC) in multiple sclerosis (MS) patients with refractory lower urinary tract symptoms (LUTS). The aim of this study is to evaluate the long term outcomes and morbidity of these procedures in MS patients.
Materials and methods: This is a retrospective observational study of consecutive patients (1984-2017) with MS and refractory LUTS who underwent AC with or without a continent/incontinent abdominal stoma or urinary diversion. Pre and postoperative evaluations included routine labs, videourodynamic studies (VUDS), cystoscopy, and upper tract imaging. Long term outcomes and complications were assessed by… More >

View

24

Download

22

Open Access

COMMENTARY

Patrick J. Shenot
Canadian Journal of Urology, Vol.26, No.3, pp. 9781-9781, 2019
Abstract This article has no abstract. More >

View

23

Download

25

Open Access

HOW I DO IT

Judd W. Moul
Canadian Journal of Urology, Vol.26, No.3, pp. 9782-9786, 2019
Abstract Urologistshavebeenusingoralnonsteroidalantiandrogens (AA) for 30 years as a component of combined androgen blockade. In February 2018, a new third generation AA, apalutamide, became available for the frst time for non-metastatic (M0) castrate resistant prostate cancer (CRPC). Apalutamide was found to delay the presence of metastases (metastases free survival-MFS) by approximately 2 years versus placebo in M0 CRPC. While overall survival beneft has yet to be established, the MFS beneft is clinically meaningful and urology practices should be equipped to manage patients using thisneworalagent.Sincethemajorityofpatientsremain under urologic care when this disease stage develops and becausethedrugisstraightforwardtoadminister,urology practices are ideal More >

View

23

Download

23

Open Access

HOW I DO IT

Christopher H. Cantrill¹, Kevin C. Zorn², Dean S. Elterman³, Ricardo R. Gonzalez⁴
Canadian Journal of Urology, Vol.26, No.3, pp. 9787-9793, 2019
Abstract Benign prostatic hyperplasia (BPH) and accompanying lower urinary tract symptoms (LUTS) sits in the top ten prominent and costly disease conditions in men over 50 years of age. In the United States it is the most common diagnosis made by urologists for men 45 to 74 years of age. Twenty percent of the population will reach 65 years of age or older by 2030, and those over 85 years will represent the fastest growing segment of our population. The prevalence of symptomatic BPH increases proportionally with the aging population. It is estimated that BPH now More >

View

25

Download

25

Open Access

RESIDENT’S CORNER

David Harriman¹, Alexei Mikhailov², Jeffrey Rogers¹, Robert Stratta¹, Alan Farney¹
Canadian Journal of Urology, Vol.26, No.3, pp. 9794-9798, 2019
Abstract Large renal cell carcinomas (RCC) arising in allograft kidney transplants are rarely encountered. The distinct RCC sub-type, clear cell papillary RCC (CP-RCC), has mostly been described in non-immunosuppressed patients. Here we report the presentation, management and pathologic diagnosis of a large (11.2 cm, pT2b), multifocal, CP-RCC in a poorly functioning renal allograft of a 63-year-old woman 19 years following kidney transplant. Preoperative angiographic kidney embolization was successfully performed prior to allograft nephrectomy, with an excellent surgical, oncologic and clinical outcome. More >

View

30

Download

27

Open Access

RESIDENT’S CORNER

Alexander H. Wu¹, Supreet Kaur², Sharon Peng², Ashima Kapoor¹, Michael Maroules²
Canadian Journal of Urology, Vol.26, No.3, pp. 9799-9801, 2019
Abstract Most germ cell tumors are located in the gonads however there are instances where these tumors are located elsewhere in which are termed extragonadal germ cell tumors. When primary lesion of the testicular tumor has regressed, the term “burned-out testicular tumor” has been proposed. We herein report the first case of burned-out seminoma of the testis presenting as a cervical spinal mass causing cord compression with bone metastasis. More >

View

25

Download

24